142 related articles for article (PubMed ID: 12068389)
1. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
Stadtmauer EA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
[TBL] [Abstract][Full Text] [Related]
2. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
3. Histamine in cancer immunotherapy: a preclinical background.
Hellstrand K
Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
5. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
6. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
7. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
8. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
10. Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.
Rowe JM; Nilsson BI; Simonsson B
Leuk Lymphoma; 1993 Nov; 11(5-6):321-9. PubMed ID: 7510190
[TBL] [Abstract][Full Text] [Related]
11. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
12. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
Sander FE; Nilsson M; Rydström A; Aurelius J; Riise RE; Movitz C; Bernson E; Kiffin R; Ståhlberg A; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Cancer Immunol Immunother; 2017 Nov; 66(11):1473-1484. PubMed ID: 28721449
[TBL] [Abstract][Full Text] [Related]
13. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options in the management of renal cell carcinoma.
Glaspy JA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):41-6. PubMed ID: 12068388
[TBL] [Abstract][Full Text] [Related]
15. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
17. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
19. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Brune M; Romero AI; Hellstrand K
Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
[No Abstract] [Full Text] [Related]
20. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?
Klingemann HG; Phillips GL
Leuk Lymphoma; 1995 Feb; 16(5-6):397-405. PubMed ID: 7787749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]